A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma

Authors

Josefine Krüger,[1] Matthias Obenaus,[1] Igor Wolfgang Blau,[2] Dana Hoser,[3] Martin Vaegler,[4] Hana Rauschenbach,[4] Ioannis Anagnostopoulos,[5] Korinna Jöhrens,[5] Vivian Scheuplein,[6] Elisa Kieback,[6] Judith Böhme,[5] Ann-Christin von Brünneck,[5] Jan Krönke,[1,7] Antonia Busse,[1,6,7] Gerald Willimsky,[3,7,8] Thomas Blankenstein,[6] Antonio Pezzutto,[1,6] Ulrich Keller[1,6,7] and Axel Nogai[1]

[1]Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; [2]Department of Hematology, Oncology and Cancer Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; [3]Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin; [4]Experimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, Berlin; [5]Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; [6]Max-Delbrück-Center for Molecular Medicine, Berlin; [7]German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, Berlin and [8]German Cancer Research Center (DKFZ), Heidelberg, Germany

Correspondence:
A. NOGAI - nogai@onkologie-tiergarten.de
U. KELLER - ulrich.keller@charite.de

A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma

Josefine Krüger[1], Matthias Obenaus[1], Igor Wolfgang Blau[2], Dana Hoser[3], Martin Vaegler[4], Hana Rauschenbach[4], Ioannis Anagnostopoulos[5], Korinna Jöhrens[5], Vivian Scheuplein[6], Elisa Kieback[6], Judith Böhme[5], Ann-Christin von Brünneck[5], Jan Krönke[1,7], Antonia Busse[1,6,7], Gerald Willimsky[3,7,8], Thomas Blankenstein[6], Antonio Pezzutto[1,6], Ulrich Keller[1,6,7], Axel Nogai[1]

[1]Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12203 Berlin, Germany

[2]Department of Hematology, Oncology and Cancer Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany

[3]Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

[4]Experimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, 13125 Berlin, Germany

[5]Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin

[6]Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany

[7]German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany

[8]German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

Supplementary Data:

Supplementary Tables

SUPPLEMENTARY TABLES

Supplemental Table 1. Patient characteristics of the diagnostic MAGE-A1 expression study.

	n (%)
all patients	213 (100)
female	75 (35)
Disease stage	
first diagnosis	92 (43)
relapse	114 (54)
sequentially primary and relapse	7 (3)
Occurrence of EMD at any time of disease	84 (39)
EM-B	66 (31)
EM-E	18 (9)
FiSH results available	131 (62)
standard risk	59 (28)
high risk, defined as...	72 (34)
Gain(1q21) or amplification(1q21)	55 (26)
del(17p)	18 (8)
t(4;14)	21 (10)
t(14;16)	7 (3)

EMD: extramedullary disease

EM-B: bone-related extramedullary myeloma

EM-E: extraosseous extramedullary myeloma

Supplemental Table 2. Phase 1 study of TCR-1367 T cells, patient characteristics.

Patient ID	004	006
Sex	female	male
Age	57	62
EMD	no	yes (EM-B)
MAGE-A1+ myeloma cells in BM at screening |%|	80%	90%
Cytogenetics/FiSH	standard risk	high risk (+1q21)
Lines of previous therapies	4	7
Refractory status		
IMiDs	yes	yes
PI	yes	yes
any anti-CD38 antibody	yes	yes
any anti-BCMA directed therapy	no	yes

EMD: extramedullary disease

BM: bone marrow

IMiDs: immunomodulatory drugs

PI: proteasome inhibitors

BCMA: B-cell maturation antigen

Supplemental Table 3. Phase 1 study of TCR-1367 T cells, adverse events.

Patient 004			
Term	**Grade**	**TEAE?**	**Causality to T-cell therapy**
Nausea	2	no	Not related
Pyrexia	1	no	Not related
Pain in extremity	1	yes	Possible
Arthralgia	1	yes	Possible
Cancer pain	1	yes	Possible
Sinus tachycardia	1	yes	Possible
Pyrexia	1	yes	Possible
Pyrexia	1	yes	Possible
Chest pain	1	yes	Possible
Neutropenia	4	yes	Possible
Anemia	2	yes	Possible
Anemia	2	yes	Possible
White blood cell count decreased	2	yes	Not related
White blood cell count decreased	4	yes	Possible

Patient 006			
Term	**Grade**	**TEAE?**	**Causality to T-cell therapy**
Anemia	3	no	Not related
Platelet count decreased	4	no	Not related
Urinary tract infection	2	no	Not related
White blood cell count decreased	3	no	Not related
Nausea	2	no	Not related
Lymphocyte count decreased	4	no	Not related
Dry mouth	1	no	Not related
Depression	2	yes	Not related

Petechiae	1	yes	Not related
Neoplasm progression	1	yes	Not related
Neoplasm progression	3	yes	Not related
Mouth hemorrhage	1	yes	Not related
Monoparesis	3	yes	Not related

TEAE: treatment-emergent adverse events